Monitoring Lipids in Patients Treated With Ziprasidone or Aripiprazole

Despite a consensus that lipids should be monitored in all patients treated with a second-generation antipsychotic, lipid monitoring is inconsistent for patients receiving ziprasidone or aripiprazole. Here's why, and how an investigation at one VA medical center prompted practice recommendations.